Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant alpha interferon.
1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) has recently proved to be a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) in vitro. Combinations of HEPT and recombinant alpha interferon (IFN-alpha) synergistically inhibit the replication of HIV-1 in MT-4 cells at non-toxic concentrations. Synergistic inhibition of HIV-1 replication has also been observed in peripheral blood lymphocytes. These results indicate that the combination of HEPT with IFN-alpha should be further pursued in the treatment of retrovirus infections [i.e. acquired immune deficiency syndrome (AIDS)].
Ito
M
M
Department of Bacteriology, Fukushima Medical College, Japan.
Baba
M
M
Shigeta
S
S
De Clercq
E
E
Walker
R T
RT
Tanaka
H
H
Miyasaka
T
T
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000382:microbiology; D002478:Cells, Cultured; D003588:Cytopathogenic Effect, Viral; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015497:HIV-1 / Q000187:drug effects* / Q000254:growth & development / Q000502:physiology; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology* / Q000627:therapeutic use; D011994:Recombinant Proteins; D013941:Thymine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects*
D007370:Interferon Type I; D011994:Recombinant Proteins; C061818:1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine; D013941:Thymine